Find a Clinical Trial

Trial Description: This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with incurable cancer who report fatigue and have low testosterone levels.

• Conditions: cancer, fatigue, hypogonadism male
• Phase: II
• Trial ID: NCT04301765
• Protocol ID: 20-183

Trial Description: This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors

• Conditions: bladder cancer, colorectal cancer (crc), gastric cancer, head and neck cancer, lung cancer, mesothelioma, metastatic cancer, renal cell carcinoma (rcc), solid tumors, uc (urothelial cancer)
• Phase: I
• Trial ID: NCT02903914
• Protocol ID: 17-427

Trial Description: This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: - Pembrolizumab (MK3475) - Ibrutinib - Rituximab (or biosimilar

• Conditions: primary central nervous system lymphoma, recurrent cancer
• Phase: I/II
• Trial ID: NCT04421560
• Protocol ID: 20-144

Trial Description: This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced solid tumors. This study will also determine the recommended phase 2 dose (RP2D

• Conditions: advanced cancer, angiosarcoma, colorectal cancer without liver metastases, endometrial cancer, fibrolamellar carcinoma, melanoma, non-small-cell lung cancer, ovarian cancer, prostate cancer
• Phase: I
• Trial ID: NCT03860272
• Protocol ID: 19-132

Trial Description: Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity

• Conditions: bile duct cancer, bladder cancer, breast neoplasm malignant primary, cervical cancer, cholangiocarcinoma, colo-rectal cancer, head and neck cancer, head and neck carcinoma, her-2 gene amplification, her2 gene mutation, her2 positive gastric cancer, her2-positive breast cancer, larynx cancer, lip cancer stage i, liver cancer, lung cancer, mouth cancer, mucinous adenocarcinoma gastric, mucinous breast cancer recurrent, mucoepidermoid carcinoma, palate cancer, pancreatic cancer, primary peritoneal carcinoma, prostate cancer, rare diseases, rectal cancer, rectal cancer stage i, rectal cancer stage ii, rectal cancer stage iii, recurrent breast cancer, recurrent colon cancer, recurrent gastric cancer, recurrent ovarian carcinoma, recurrent prostate cancer, recurrent renal cell cancer, salivary gland cancer, salivary gland carcinoma, salivary gland neoplasms, salivary gland tumor, skin cancer, solid tumor, tongue cancer, tonsil cancer, urologic cancer
• Phase: I/II
• Trial ID: NCT03602079
• Protocol ID: 18-421

Trial Description: The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

• Conditions: cancer, colon cancer, colon cancer liver metastasis, colonic neoplasms, malignancy, metastatic cancer, metastatic colon cancer, metastatic lung cancer, metastatic melanoma, metastatic nonsmall cell lung cancer, metastatic pancreatic cancer, neoplasia, neoplasm, neoplasm metastasis, non small cell lung cancer metastatic, pancreas adenocarcinoma, pancreas cancer, pancreas neoplasm, pancreatic cancer
• Phase: I
• Trial ID: NCT03415126
• Protocol ID: 18-228

Trial Description: This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody

• Conditions: bladder cancer, colorectal cancer, head and neck cancer, melanoma, non-small cell lung cancer, other solid cancers, renal cancer, triple negative breast cancer
• Phase: I
• Trial ID: NCT03289962
• Protocol ID: 18-051

Trial Description: The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001 PROBODY is a trademark of CytomX Therapeutics, Inc

• Conditions: breast cancer, head and neck cancer, non small cell lung cancer, ovarian cancer, solid tumor adult
• Phase: I/II
• Trial ID: NCT03149549
• Protocol ID: 17-368

Trial Description: A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors

• Conditions: colorectal cancer, head and neck cancer, metastatic cancer, pancreatic cancer, solid tumor, urothelial carcinoma
• Phase: I/II
• Trial ID: NCT04666688
• Protocol ID: 20-668

Trial Description: This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: - 9-ING-41 (a GSK-3β inhibitor) - Carboplatin chemotherapy

• Conditions: adenoid cystic carcinoma, metastatic cancer, recurrent salivary gland cancer, salivary gland cancer
• Phase: II
• Trial ID: NCT05010629
• Protocol ID: 21-384

Trial Description: This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.

• Conditions: cdk gene mutation, metastatic malignant neoplasm in the brain, metastatic malignant solid neoplasm, ntrk family gene mutation, pi3k gene mutation, ros1 gene mutation
• Phase: II
• Trial ID: NCT03994796
• Protocol ID: 19-553

Trial Description: This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in this study is: -Abemaciclib

• Conditions: cancer
• Phase: II
• Trial ID: NCT03310879
• Protocol ID: 17-343

Trial Description: This was a 4-part (Part A, Part B, Part C and Part D), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors. Part A was a repeat dose, dose escalation and expansion phase that identified the recommended phase II dose (RP2D) of trametinib monotherapy. Part B evaluated the preliminary activity of trametinib monotherapy in 4 disease-specific cohorts of subjects. Part C was aimed to determine the safety, tolerability and preliminary activity of the RP2D of trametinib in combination with a limited dose escalation of dabrafenib

• Conditions: cancer
• Phase: I/II
• Trial ID: NCT02124772
• Protocol ID: 15-079

Trial Description: This research study is studying a combination of a targeted therapy and an immune therapy as a possible treatment. The drugs involved in this study are: - Prexasertib (LY2606368) - LY3300054

• Conditions: cancer
• Phase: I
• Trial ID: NCT03495323
• Protocol ID: 18-008

Trial Description: JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy

• Conditions: cancer
• Phase: I
• Trial ID: NCT02904226
• Protocol ID: 16-501

Trial Description: The primary objective of this phase II trial is to determine tumor overall response rate (ORR) in molecularly selected patients with measurable disease as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST), before versus after 16 weeks of treatment across tumor types in each arm of the study

• Conditions: cancer
• Phase: II
• Trial ID: NCT02576444
• Protocol ID: 16-314

Trial Description: This is an open-label, single arm, dose escalation study in patients with advanced cancers.

• Conditions: cancer
• Phase: I
• Trial ID: NCT02552953
• Protocol ID: 15-281

Trial Description: This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors. The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab

• Conditions: advanced solid tumors, her2-positive breast cancer
• Phase: I
• Trial ID: NCT04487236
• Protocol ID: 20-683

Trial Description: This research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.

• Conditions: head & neck cancer, lung cancer squamous cell, pancreatic cancer, solid tumors
• Phase: I
• Trial ID: NCT03065062
• Protocol ID: 16-499

Trial Description: This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111), for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.

• Conditions: glioblastoma, recurrent glioblastoma
• Phase: II
• Trial ID: NCT04406272
• Protocol ID: 19-792

Trial Description: In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475

• Conditions: advanced cancer, advanced solid tumors, anal cancer, anal carcinoma, bile duct cancer, biliary cancer, carcinoid tumor, cervical cancer, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, endometrial cancer, endometrial carcinoma, mesothelioma, neuroendocrine tumor, parotid gland cancer, salivary cancer, salivary gland cancer, salivary gland carcinoma, small cell lung cancer (sclc), small cell lung carcinoma, thyroid cancer, thyroid carcinoma, vulvar cancer, vulvar carcinoma
• Phase: II
• Trial ID: NCT02628067
• Protocol ID: 16-030

Trial Description: The purpose of this study is to test whether a mobile application developed to help people with cancer pain is useful and helpful to patients with cancer.

• Conditions: active cancer, active cancer treatment, advanced cancer, chronic pain due to cancer, palliative care
• Phase: Feasibility / Pilot
• Trial ID: NCT05403801
• Protocol ID: 21-719

Trial Description: The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.

• Conditions: colon cancer, esophageal cancer, gastric cancer, gastrointestinal cancer, pancreatic cancer, rectal cancer
• Phase: II
• Trial ID: NCT04674267
• Protocol ID: 20-275

Trial Description: The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first administer SY-5609 in combination with gemcitabine and then SY-5609 in combination with gemcitabine and nab-paclitaxel in participants with pancreatic ductal adenocarcinoma (PDAC) .

• Conditions: advanced solid tumor, breast cancer, pancreatic cancer, small-cell lung cancer
• Phase: I
• Trial ID: NCT04247126
• Protocol ID: 20-211

Trial Description: This research study is studying palbociclib as a possible treatment for recurrent brain metastases. - Pfizer, a pharmaceutical company, is supporting this research study by providing the study drug as well as funding for research activities

• Conditions: metastatic malignant neoplasm to brain
• Phase: II
• Trial ID: NCT02896335
• Protocol ID: 16-254

Trial Description: This research study is studying a new type of vaccine as a possible treatment for patients with glioblastoma. This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the intervention to use for further studies. "Investigational" means that the intervention is being studied and that research doctors are trying to find more about it. It also means that the FDA (U.S. Food and Drug Administration) has not approved the Personalized NeoAntigen Cancer Vaccine for any use in patients

• Conditions: glioblastoma
• Phase: I
• Trial ID: NCT02287428
• Protocol ID: 14-362

Trial Description: The purpose of this study is to increase serious illness conversations (SICs) about patients goals and preferences regarding their healthcare between patients with cancer and their oncology clinicians and improved care provided near the end of life.

• Conditions: breast cancer, gastrointestinal cancer, genitourinary cancer, gynecologic cancer, thoracic cancer
• Phase: Not Applicable
• Trial ID: NCT05629065
• Protocol ID: 22-501

Trial Description: Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

• Conditions: breast cancer, cervical cancer, cholangiocarcinoma, colorectal cancer, endocervical cancer, esophageal cancer, gastric cancer, glioblastoma, melanoma, mesothelioma, non small cell lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, squamous cell carcinoma of head and neck
• Phase: I/II
• Trial ID: NCT04913337
• Protocol ID: 21-735

Trial Description: This research study aims to explore the feasibility and acceptability of an adapted resiliency group program, called the Relaxation Response Resiliency Program (3RP-AYA), to reduce stress and promote stress-management among adolescents and young adults who have completed treatment for cancer.

• Conditions: cancer
• Phase: Not Applicable
• Trial ID: NCT03768336
• Protocol ID: 18-428

Trial Description: PATHFINDER is a prospective, multi-center study in which approximately 6,200 participants will be enrolled. An investigational multi-cancer early detection test, developed by GRAIL, will be ordered by and results returned to a study investigator. In cases with a "signal detected" test result (with a predicted or indeterminate tissue of origin (TOO)), the diagnostic work-up will not be dictated by the protocol, but will instead be coordinated by the ordering and treating medical team at the enrolling sites based on the participant's clinical condition, recommendations

• Conditions: cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT04241796
• Protocol ID: 19-837

Trial Description: This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2. Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology

• Conditions: advanced solid tumors, breast cancer, ovarian cancer
• Phase: I
• Trial ID: NCT03134638
• Protocol ID: 17-236

Trial Description: Part 1: to assess the safety and tolerability of pyrotinib and to define the maximum tolerated dose (MTD) of pyrotinib in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors (metastatic breast cancer, gastric cancer, or other solid tumors that have no targeted agent as standard of care). Part 2: to estimate the overall response rate (ORR) for patients with HER2-positive metastatic breast cancer (mBC) and HER2 mutant non-small cell lung cancer (NSCLC) treated at the RP2D (or MTD).

• Conditions: breast cancer, gastric cancer, nsclc, solid tumors
• Phase: I
• Trial ID: NCT02500199
• Protocol ID: 16-265

Trial Description: This is an open-label, exploratory study to evaluate nivolumab with or without ipilimumab based on percentage of tumoral CD8 cells at the time of treatment in participants with varying advanced solid tumors. Participants who have a tumor with ≥ 15% CD8 cells (classified as CD8 high) will receive nivolumab monotherapy, and participants who have a tumor with < 15% CD8 cells (classified as CD8 low) will receive ipilimumab in combination with nivolumab

• Conditions: advanced metastatic cancer, advanced prostate cancer
• Phase: Feasibility / Pilot
• Trial ID: NCT03651271
• Protocol ID: 18-741

Trial Description: This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.

• Conditions: biliary cancer, colorectal cancer, gastric cancer, pancreatic cancer
• Phase: I
• Trial ID: NCT02908451
• Protocol ID: 17-137

Trial Description: This research is being done to see how effective the drug niraparib is against cancer that has metastasized to the central nervous system (CNS). - This research study involves the study drug niraparib.

• Conditions: central nervous system cancer, metastatic cancer
• Phase: II
• Trial ID: NCT04992013
• Protocol ID: 21-154

Trial Description: The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines (called binimetinib and cetuximab) in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 1 or 2 times a day

• Conditions: colorectal cancer, glioma, melanoma, non-small-cell lung cancer, thyroid cancer
• Phase: I
• Trial ID: NCT05355701
• Protocol ID: 22-523

Trial Description: This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation

• Conditions: advanced cancer, malignant neoplastic disease, metastatic cancer
• Phase: I/II
• Trial ID: NCT03785249
• Protocol ID: 19-047

Trial Description: This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation

• Conditions: advanced cancer, malignant neoplastic disease, metastatic cancer
• Phase: I/II
• Trial ID: NCT04330664
• Protocol ID: 20-128

Trial Description: This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2

• Conditions: advanced solid tumors, carcinosarcoma, ccne1 amplification, endometrial cancer, esophageal adenocarcinoma, gastric cancer, her2-negative breast cancer, hr+ breast cancer, ovarian cancer
• Phase: I/II
• Trial ID: NCT05252416
• Protocol ID: 22-142

Trial Description: This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain. The names of the study drugs involved in this study are: - Atezolizumab - Pertuzumab - Trastuzumab

• Conditions: central nervous system metastases, her2-positive metastatic breast cancer
• Phase: II
• Trial ID: NCT03417544
• Protocol ID: 17-546

Trial Description: This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

• Conditions: any solid tumor, colon cancer, medullary thyroid cancer, non-small cell lung cancer
• Phase: I/II
• Trial ID: NCT03157128
• Protocol ID: 17-241

Trial Description: This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

• Conditions: adenoid cystic carcinoma, advanced solid tumor, cervical cancer, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, metastatic head and neck carcinoma, metastatic melanoma, metastatic prostate cancer, metastatic renal cell carcinoma, non small cell lung cancer, ovarian cancer, pancreas cancer, salivary gland cancer, sarcomas, small cell lung cancer, urothelial carcinoma
• Phase: I
• Trial ID: NCT04140526
• Protocol ID: 22-076

Trial Description: The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

• Conditions: advanced cancer, colorectal cancer, metastatic melanoma, metastatic non-small cell lung cancer
• Phase: I
• Trial ID: NCT02857270
• Protocol ID: 16-456

Trial Description: This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent

• Conditions: adrenocortical carcinoma, advanced solid tumours, breast cancer, cervical cancer, endometrial cancer, head and neck squamous cell carcinoma (hnscc), her2-negative breast cancer, ovarian cancer, triple negative breast cancer (tnbc), uveal melanoma
• Phase: I
• Trial ID: NCT03746431
• Protocol ID: 19-824

Trial Description: The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab. This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a 3+3+3 design in patients with advanced solid tumors of any histology. Once the MTD/MAD is determined, a Cohort Expansion Phase will be enrolled to further characterize safety and initial anti-tumor activity in patients with specific

• Conditions: advanced cancer, colorectal cancer, cutaneous melanoma, prostate cancer metastatic, solid tumor adult, squamous cell non small cell lung cancer
• Phase: I
• Trial ID: NCT03761017
• Protocol ID: 19-090

Trial Description: This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indication

• Conditions: advanced solid tumor, breast cancer, colorectal cancer, gynecologic cancer, hormone receptor/growth factor receptor-negative breast cancer, lung adenocarcinoma, ovarian cancer, renal cell carcinoma, triple negative breast cancer
• Phase: I/II
• Trial ID: NCT04691375
• Protocol ID: 21-599

Trial Description: This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.

• Conditions: breast cancer, metastatic prostate cancer, ovarian cancer, pancreatic cancer
• Phase: Not Applicable
• Trial ID: NCT04330716
• Protocol ID: 19-652

Trial Description: SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video

• Conditions: gastrointestinal cancer, hematologic cancer, thoracic cancer
• Phase: Not Applicable
• Trial ID: NCT05375643
• Protocol ID: 21-709

Trial Description: The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy. This study compared progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemotherapy. In addition, this study evaluated the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy and assessed the safety and tolerability of EV, as well as, the quality of life (QOL) and Patient Reported Outcomes (PRO) parameters.

• Conditions: bladder cancer, ureteral cancer, urothelial cancer
• Phase: III
• Trial ID: NCT03474107
• Protocol ID: 18-386

Trial Description: The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal, or prostate cancer patients. The names of the study interventions involved in this study are: - Supervised aerobic and resistance exercise (SUP) - virtually supervised 16- week aerobic and resistance exercise performed at home via Zoom. - Unsupervised aerobic and resistance exercise (UNSUP) - home-based 16- week aerobic and resistance exercise. - Attention control (AC) - 16-week home-based stretching.

• Conditions: breast cancer, colorectal cancer, prostate cancer
• Phase: Not Applicable
• Trial ID: NCT05327452
• Protocol ID: 21-559